Johnson & Johnson beat earnings estimates for the fourth quarter but gave guidance for the fiscal year on the low side of expectations. J&J mentioned the medical device tax included in the Affordable Care Act several times in the company's conference call. Johnson & Johnson outlined several ways to bring down healthcare costs and suggested focusing on one product's costs was overlooking the bigger picture.

Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

If you liked this article you might like

Roku, Nucana and Other IPOs That Should Be on Your Radar in 2017

Crazy Weak U.S. Dollar Will Make These 10 Companies Huge Winners

Cramer: Goldman's Downgrade Of J&J Is 'Questionable'

Johnson & Johnson Stock Sinks, Goldman Downgrades to 'Sell'

The Best Companies for Women